Effect of C-reactive protein reduction on paroxysmal atrial fibrillation
- 30 November 2005
- journal article
- research article
- Published by Elsevier BV in American Heart Journal
- Vol. 150 (5), 1064.e7-1064.e12
- https://doi.org/10.1016/j.ahj.2005.06.032
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT)American Heart Journal, 2005
- Frequency of elevation of C-reactive protein in atrial fibrillationThe American Journal of Cardiology, 2004
- Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillationEuropean Heart Journal, 2004
- Usefulness of Ambulatory 7-Day ECG Monitoring for the Detection of Atrial Fibrillation and Flutter After Acute Stroke and Transient Ischemic AttackStroke, 2004
- New hope for the prevention of recurrent atrial fibrillation.European Heart Journal, 2004
- Analysis of Cause-Specific Mortality in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) StudyCirculation, 2004
- The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis modelCardiovascular Research, 2004
- The incidence of asymptomatic paroxysmal atrial fibrillation in patients treated with propranolol or propafenoneInternational Journal of Cardiology, 1996
- Identification of Atrial Fibrillation Episodes in Ambulatory Electrocardiographic Recordings: Validation of a Method for Obtaining Labeled R‐R Interval FilesPacing and Clinical Electrophysiology, 1995
- Clinical features of paroxysmal atrial fibrillation an observation of 94 patients.Japanese Heart Journal, 1981